DCGI APPROVES COMMERCIAL LAUNCH OF LOW COST COVID-19 TEST ‘FELUDA’

The Drugs Controller General of India has approved the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.

The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use.CRISPR is a genome editing technology to diagnose diseases.

The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).

“The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the statement said.

Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.

Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.

He emphasised that this shows the interconnectedness of scientific knowledge and technology and the innovation of the young research team led by Debojyoti Chakraborty and Souvik Maiti.

Inputs from The print and India tv.

Leave a Reply

Your email address will not be published. Required fields are marked *